Skip to main content

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Safety and Effectiveness of STSF Catheter Evaluated for Treating Symptomatic Persistent Atrial Fibrillation (PsAF)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Safety and Effectiveness of STSF Catheter Evaluated for Treating Symptomatic Persistent Atrial Fibrillation (PsAF)

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)

Phase I Trial of BAY1251152 for Advanced Blood Cancers

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Phase I Trial of BAY1251152 for Advanced Blood Cancers

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 109
  • Page 110
  • Page 111
  • Page 112
  • Page 113
  • Page 114
  • Page 115
  • Page 116
  • Page 117
  • …
  • Next page Next
  • Last page Last
Subscribe to